{"id":692864,"date":"2022-10-06T08:31:44","date_gmt":"2022-10-06T12:31:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/"},"modified":"2022-10-06T08:31:44","modified_gmt":"2022-10-06T12:31:44","slug":"tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/","title":{"rendered":"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research,<\/em><br \/>\n          <em>to Chair \u201cNew Approaches to Solid Tumor Targeting\u201d Session<\/em><br \/>\n          \n        <\/li>\n<li style=\"margin-bottom:6pt\">\n          <em>Nicholas DeVito, M.D, Duke University School of Medicine, to present TPST-1495 preclinical data<\/em>\n        <\/li>\n<\/ul>\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Oct.  06, 2022  (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class<sup>1<\/sup> therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Dara Burdette, Ph.D., Senior Director of Discovery Research at Tempest, will present on the company\u2019s TREX1 pipeline asset and will serve as chairperson for the \u201cNew Approaches to Solid Tumor Targeting\u201d session at the Emerging Technologies for IO Targeting and Discovery Summit taking place October 13-14, 2022 in Boston, MA.<\/p>\n<p align=\"justify\">\n        <u>TREX1 Presentation<\/u>\n      <\/p>\n<p align=\"justify\">Dr. Burdette\u2019s presentation will describe the company\u2019s approach to identify and characterize novel small molecule inhibitors of the 3\u2019-5\u2019 DNA repair exonuclease, TREX1. TREX1 inhibits cGAS\/STING signaling and is induced in tumor cells due to genetic instability or therapeutic intervention. Tempest\u2019s program aims to generate an anti-tumor response through selectively activating the STING pathway in advanced metastatic cancers with orally available small molecule inhibitors of TREX1.<\/p>\n<p align=\"justify\">Presentation details:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:8%;width:8%;min-width:8%;text-align: left;vertical-align: middle;vertical-align: top\">Title:<\/td>\n<td style=\"max-width:92%;width:92%;min-width:92%;text-align: left;vertical-align: middle;vertical-align: top\">Small Molecules Targeting the 3\u2019-5\u2019 DNA Repair Exonuclease TREX1 Selectively<br \/>Activate the STING Pathway and Induce Tumor-Specific Immunity<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Date:<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Thursday, October 13, 2022<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Time:<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">2:40 p.m. EDT<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <u>TPST-1495 Presentation<\/u>\n      <\/p>\n<p align=\"justify\">In addition, Nicholas DeVito, M.D., a medical oncologist and medical instructor in the laboratory of Dr. Brent Hanks, M.D., Ph.D. at Duke University School of Medicine, will be giving a presentation describing pre-clinical results with TPST-1495, Tempest\u2019s clinical-stage dual inhibitor of the EP2 and EP4 prostaglandin E2 receptors, in mice bearing tumors with designated gene expression profiles.<\/p>\n<p align=\"justify\">Presentation details:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:8%;width:8%;min-width:8%;text-align: left;vertical-align: middle;vertical-align: top\">Title:<\/td>\n<td style=\"max-width:92%;width:92%;min-width:92%;text-align: left;vertical-align: middle;vertical-align: top\">Understanding Tumor-Mediated Immune Evasion to Develop Biomarkers toward Rational Therapeutic Combinations<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Date:<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Wednesday, October 12, 2022<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Time:<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">8:40 a.m. EDT<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About Tempest Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company\u2019s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPAR\u03b1 and EP2\/EP4, respectively. Both programs are advancing through clinical trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS\/STING pathway. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Yq01ZNYbnrsQmJN8PqawV1KgcEIbRgxPc-GERJdTdqkQ2dj8ucSNaRUA47uOf3Rio45GA7CNpq8ridpWtBEKVw==\" rel=\"nofollow noopener\" target=\"_blank\">www.tempesttx.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contacts:<\/strong><br \/>\n        <br \/>Sylvia Wheeler<br \/>Wheelhouse Life Science Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bQ13bZekqaDV_atSL_vjqam-WgqBf3ITQOBnvCep3jaSXApUOkvILX17mwYRPdtq-SjBdnS3DJManuMGXg9k1jrDrmd_mu364Klk_uhrUyDTX8b8_ug1A4FnPo36iXl1\" rel=\"nofollow noopener\" target=\"_blank\"><u>swheeler@wheelhouselsa.com<\/u><\/a><\/p>\n<p>Aljanae Reynolds <br \/>Wheelhouse Life Science Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DVGbdV-kqKmhPHzjZ7fC60qJnGXnWmd9GhtOkOqzSTatwzEjcI4iY57sZQrUmzVIoECI8cGkPSsIMqrztz5NpI5sO_bJoBEyokB9krgqIRj_rMkm4SyoH2kZwVb8Umd0\" rel=\"nofollow noopener\" target=\"_blank\">areynolds@wheelhouselsa.com<\/a><\/p>\n<hr \/>\n<p>\n        <sup>1<\/sup> If approved by the FDA<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTcwMSM1MTg5NDUyIzIxODk5MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MWZjMzYwZTYtNmMxZC00Yjk1LWEwMTUtMDEyYjdlMTk2MDFhLTEyMDE0ODc=\/tiny\/Tempest-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair \u201cNew Approaches to Solid Tumor Targeting\u201d Session Nicholas DeVito, M.D, Duke University School of Medicine, to present TPST-1495 preclinical data SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Dara Burdette, Ph.D., Senior Director of Discovery Research at Tempest, will present on the company\u2019s TREX1 pipeline asset and will serve as chairperson for the \u201cNew Approaches to Solid Tumor Targeting\u201d session at the Emerging Technologies for IO Targeting and Discovery Summit taking place October 13-14, 2022 in Boston, MA. TREX1 Presentation Dr. Burdette\u2019s presentation will describe &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692864","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair \u201cNew Approaches to Solid Tumor Targeting\u201d Session Nicholas DeVito, M.D, Duke University School of Medicine, to present TPST-1495 preclinical data SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Dara Burdette, Ph.D., Senior Director of Discovery Research at Tempest, will present on the company\u2019s TREX1 pipeline asset and will serve as chairperson for the \u201cNew Approaches to Solid Tumor Targeting\u201d session at the Emerging Technologies for IO Targeting and Discovery Summit taking place October 13-14, 2022 in Boston, MA. TREX1 Presentation Dr. Burdette\u2019s presentation will describe &hellip; Continue reading &quot;Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-06T12:31:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTcwMSM1MTg5NDUyIzIxODk5MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit\",\"datePublished\":\"2022-10-06T12:31:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/\"},\"wordCount\":445,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTcwMSM1MTg5NDUyIzIxODk5MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/\",\"name\":\"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTcwMSM1MTg5NDUyIzIxODk5MzQ=\",\"datePublished\":\"2022-10-06T12:31:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTcwMSM1MTg5NDUyIzIxODk5MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTcwMSM1MTg5NDUyIzIxODk5MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/","og_locale":"en_US","og_type":"article","og_title":"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit - Market Newsdesk","og_description":"Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair \u201cNew Approaches to Solid Tumor Targeting\u201d Session Nicholas DeVito, M.D, Duke University School of Medicine, to present TPST-1495 preclinical data SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Dara Burdette, Ph.D., Senior Director of Discovery Research at Tempest, will present on the company\u2019s TREX1 pipeline asset and will serve as chairperson for the \u201cNew Approaches to Solid Tumor Targeting\u201d session at the Emerging Technologies for IO Targeting and Discovery Summit taking place October 13-14, 2022 in Boston, MA. TREX1 Presentation Dr. Burdette\u2019s presentation will describe &hellip; Continue reading \"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-06T12:31:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTcwMSM1MTg5NDUyIzIxODk5MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit","datePublished":"2022-10-06T12:31:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/"},"wordCount":445,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTcwMSM1MTg5NDUyIzIxODk5MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/","name":"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTcwMSM1MTg5NDUyIzIxODk5MzQ=","datePublished":"2022-10-06T12:31:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTcwMSM1MTg5NDUyIzIxODk5MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTcwMSM1MTg5NDUyIzIxODk5MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tempest-to-present-at-emerging-technologies-for-io-targeting-and-discovery-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692864"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692864\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}